Summary
Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension - Pipeline Review, H1 2016’, provides an overview of the Idiopathic (Essential) Hypertension pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
- The report reviews pipeline therapeutics for Idiopathic (Essential) Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Idiopathic (Essential) Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Idiopathic (Essential) Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Idiopathic (Essential) Hypertension
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Actelion Ltd
Bayer AG
Chong Kun Dang Pharmaceutical Corp.
Daiichi Sankyo Company, Limited
Eli Lilly and Company
HanAll Biopharma Co., Ltd.
Innopharmax Inc.
Lee's Pharmaceutical Holdings Limited
PhaseBio Pharmaceuticals, Inc.
Quantum Genomics SA
Sun Pharma Advanced Research Company Ltd.
Takeda Pharmaceutical Company Limited
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Idiopathic (Essential) Hypertension Overview 8
Therapeutics Development 9
Pipeline Products for Idiopathic (Essential) Hypertension - Overview 9
Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10
Idiopathic (Essential) Hypertension - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Idiopathic (Essential) Hypertension - Products under Development by Companies 14
Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 15
Actelion Ltd 15
Bayer AG 16
Chong Kun Dang Pharmaceutical Corp. 17
Daiichi Sankyo Company, Limited 18
Eli Lilly and Company 19
HanAll Biopharma Co., Ltd. 20
Innopharmax Inc. 21
Lee's Pharmaceutical Holdings Limited 22
PhaseBio Pharmaceuticals, Inc. 23
Quantum Genomics SA 24
Sun Pharma Advanced Research Company Ltd. 25
Takeda Pharmaceutical Company Limited 26
Idiopathic (Essential) Hypertension - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
(amlodipine besylate + candesartan cilexetil) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(amlodipine besylate + hydrochlorothiazide + losartan potassium) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(atorvastatin calcium + losartan potassium) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(candesartan cilexetil + nifedipine) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
azilsartan medoxomil - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
carvedilol phosphate CR - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
carvedilol phosphate SR - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CS-3150 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
lisinopril - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
LY-2623091 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PB-1046 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PB-1120 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
QGC-001 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
rostafuroxin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Idiopathic (Essential) Hypertension - Recent Pipeline Updates 58
Idiopathic (Essential) Hypertension - Dormant Projects 64
Idiopathic (Essential) Hypertension - Product Development Milestones 65
Featured News & Press Releases 65
Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure 65
Jun 12, 2013: Lee’s Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy 65
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68
List of Tables
Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H1 2016 15
Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H1 2016 16
Idiopathic (Essential) Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 17
Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 18
Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H1 2016 19
Idiopathic (Essential) Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 20
Idiopathic (Essential) Hypertension - Pipeline by Innopharmax Inc., H1 2016 21
Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 22
Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 23
Idiopathic (Essential) Hypertension - Pipeline by Quantum Genomics SA, H1 2016 24
Idiopathic (Essential) Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 25
Idiopathic (Essential) Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Assessment by Combination Products, H1 2016 28
Number of Products by Stage and Target, H1 2016 30
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Idiopathic (Essential) Hypertension Therapeutics - Recent Pipeline Updates, H1 2016 58
Idiopathic (Essential) Hypertension - Dormant Projects, H1 2016 64
List of Figures
Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 27
Assessment by Combination Products, H1 2016 28
Number of Products by Top 10 Targets, H1 2016 29
Number of Products by Stage and Top 10 Targets, H1 2016 29
Number of Products by Top 10 Mechanism of Actions, H1 2016 31
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 31
Number of Products by Routes of Administration, H1 2016 33
Number of Products by Stage and Routes of Administration, H1 2016 33
Number of Products by Molecule Types, H1 2016 35
Number of Products by Stage and Molecule Types, H1 2016 35
